Gentamicin or Amikacin for ESBL-Producing Enterobacterales Urinary Infections
For ESBL-producing Enterobacterales urinary tract infections, use gentamicin 5-7 mg/kg IV once daily or amikacin 15-20 mg/kg IV once daily, with gentamicin being the preferred first-line aminoglycoside due to broader clinical experience and established efficacy data.
Aminoglycoside Selection
The choice between aminoglycosides is straightforward:
- Gentamicin is the preferred agent, dosed at 5-7 mg/kg IV once daily 1
- Amikacin is the alternative, dosed at 15-20 mg/kg IV once daily 2, 3
Both agents demonstrate comparable efficacy for ESBL-producing organisms, but gentamicin has more extensive clinical data supporting its use in urinary infections 4, 5. Recent research confirms aminoglycosides are non-inferior to carbapenems for bloodstream infections of urinary source caused by ESBL-producing Enterobacterales, with 30-day mortality of 13.0% versus 21.2% respectively 4.
Dosing Strategy: Once-Daily Administration
The evidence strongly supports once-daily dosing over divided doses for aminoglycosides in this context:
- Once-daily dosing achieves optimal peak concentrations critical for concentration-dependent killing 1
- Comparable or superior clinical efficacy with possibly decreased nephrotoxicity compared to multiple daily dosing 1
- Peak plasma concentration optimization is essential—failure to achieve adequate peaks correlates with clinical failure 1
Important caveat: The endocarditis guidelines 6 recommend divided dosing (every 8 hours) for enterococcal endocarditis specifically, but this does NOT apply to urinary infections. For ESBL urinary infections, once-daily dosing is preferred 1.
Renal Function Considerations
Adjust your approach based on creatinine clearance:
Normal renal function (CrCl ≥80 mL/min):
- Full once-daily dose (gentamicin 5-7 mg/kg or amikacin 15-20 mg/kg) 1
Mild-moderate impairment (CrCl 30-80 mL/min):
- Give the full once-daily equivalent dose but extend the dosing interval up to 72 hours 1
- Monitor trough levels to ensure adequate clearance
Severe impairment (CrCl <30 mL/min):
- Avoid aminoglycosides if the drug cannot clear within several days 1
- Consider alternative agents (carbapenems, piperacillin-tazobactam if susceptible)
Therapeutic Drug Monitoring
Monitor trough concentrations primarily to minimize nephrotoxicity risk, not to optimize efficacy 1:
- Target trough: <1 μg/mL for gentamicin 6
- The goal is ensuring sufficiently low troughs to prevent renal toxicity
- Peak monitoring is less critical with once-daily dosing as the regimen inherently optimizes peaks
Safety Profile
Aminoglycosides demonstrate acceptable safety in urinary infections:
- Acute kidney injury rates are similar between aminoglycosides and β-lactams (12.0% vs 10.6%) 4
- Risk increases with concurrent nephrotoxic agents or pre-existing renal dysfunction 7
- Once-daily dosing may reduce nephrotoxicity compared to divided dosing 1
Clinical Efficacy Data
Recent high-quality research supports aminoglycoside use:
- Clinical improvement rates at 72 hours: 65.8% for aminoglycosides vs 55% for β-lactams 5
- Hospital stay was 1.7 days shorter with aminoglycosides 5
- Particularly effective for E. coli ESBL infections compared to other ESBL-producing Enterobacterales 4
- Combination therapy (piperacillin-tazobactam plus amikacin) shows promise as carbapenem-sparing option with rapid bacterial killing and no resistance emergence 8
Common Pitfalls to Avoid
- Do not use divided dosing (every 8 hours) for urinary infections—this is only for enterococcal endocarditis 6
- Do not underdose initially—use full weight-based dosing (5-7 mg/kg gentamicin) to achieve adequate peaks 1
- Do not continue aminoglycosides in severe renal failure where clearance is prolonged beyond several days 1
- Do not rely on aminoglycosides alone for high-inoculum infections in patients with aac(6')-Ib-cr gene, which can elevate amikacin MICs 9